Paul Rennie
Executive Director, Managing Director, Executive Chairman / Paradigm Biopharmaceuticals
Paul Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector.
His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager, and as director of business development at Soltec (FH Faulding).
Mr Rennie also led the commercialisation of Recaldent, a novel biopharmaceutical arising from research at the dental school, University of Melbourne.
He has worked in a number of positions with Mesoblast, and was the inaugural chief operating officer and executive vice president of new product development for the adult stem cell company.
